Ribobay Pharma, a leading Chinese biopharmaceutical contract research, development, and manufacturing organization (CRDMO) and a spin-off company of General Biol (Anhui) Co., Ltd, will provide cGMP-level oligonucleotide (oligo) CRDMO services to the world using Cytiva’s first FlexFactory platform for oligo manufacturing.

It is scheduled to commence manufacturing in June and expects to produce several hundred kilograms of pharmaceutical oligo per year, bringing increased reliability, speed, and efficiency to the development of novel therapies.

Jingui Yong, General Manager of Ribobay Pharma, says: “We aim to rapidly expand our oligo CRDMO business by manufacturing high-quality and diversified innovative drugs, as well as new vaccine adjuvant (CpG-ODNs) for global customers.”

With the FlexFactory platform, Ribobay Pharma can better serve their customers, providing process development support, optimization, method development, pilot production services, and customized manufacturing services.

Oligo drugs are now being applied far beyond rare diseases, including tackling chronic conditions like hyperlipidemia, hepatitis B, and diabetes, with over 1500 research pipelines around the globe. However, turning oligo drugs into commercially available products requires technology accumulation and validation, presenting high barriers in quality control and production processes. Due to the lack of industrialization and factory construction experience, large-scale production faces considerable challenges.

The collaboration between Cytiva and Ribobay Pharma is an agile response to market needs and developmental bottlenecks. Cytiva provides Ribobay Pharma with one-stop integrated services, from factory design to equipment and technologies that enable cGMP manufacturing.